Abstract
Neurodegenerative disorders are characterized by progressive accumulation of misfolded proteins that eventually advance to the death of a selected population of neurons impairing cognitive function. Neurodegenerative diseases like Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis have distinct pathophysiology. Initially, therapeutic strategies aimed at resolving the protein aggregates accumulated in the brain or resolving brain inflammation. The immune cells in the brain were considered a threat to neurodegenerative diseases due to the presence of inflammation. Therapies targeted at misfolded proteins or immune cells were failed at large. With the advancement in the profound understanding of neurodegenerative diseases and the discovery of the brain lymphatic system, the cross-talk between the brain and immune cells considered essential, and the inflammation in the brain is considered a normal cellular process. It was proposed that the brain immune system needs assistance from peripheral immune cells during the progression of neurodegenerative disease, and thus immunotherapy emerged as a new therapeutic approach. The number of preclinical and clinical studies harnessing the power of immunotherapy showed promising results. However, these strategies require further refinement with a combinatorial therapeutic approach to curb the progression of neurodegenerative diseases.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aaron DG, Paraminder D, James S (2017) Neurodegenerative disease: models, mechanisms, and a new hope. Dis Model Mech 10:499–502. https://doi.org/10.1242/dmm.030205
Afonso AFB, João CMP (2016) The production processes and biological effects of intravenous immunoglobulin. Biomol Ther 6:15. https://doi.org/10.3390/biom6010015
Amschl D, Neddens J, Havas D (2013) Time course and progression of wild typeα-Synuclein accumulation in a transgenic mouse model. BMC Neurosci 14:6
Arnold WD, Kassar D, Kissel JT (2015) Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve 51(2):157–167. https://doi.org/10.1002/mus.24497
Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology 42:631–639
Aspelund A, Antila S, Proulx ST, Karlsen TV, Karaman S, Detmar M, Wiig H, Alitalo K (2015) A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J Exp Med 212(7):991–999. https://doi.org/10.1084/jem.20142290
Baecher-Allan C, Kaskow BJ, Weiner HL (2018) Multiple sclerosis: mechanisms and immunotherapy. Neuron 97:742–768. https://doi.org/10.1016/j.neuron.2018.01.021
Bartels AL, Leenders KL (2010) Cyclooxygenase and neuroinflammation in Parkinson’s disease neurodegeneration. Curr Neuropharmacol 8:62–68
Barth MJ, Czuczman MS (2013) Ofatumumab: a novel, fully human anti-CD20monoclonal antibody for the treatment of chronic lymphocytic leukemia. Future Oncol 9(12):1829–1839
Baruch K, Rosenzweig N, Kertser A, Deczkowska A, Sharif AM, Spinrad A, Tsitsou-Kampeli A, Sarel A, Cahalon L, Schwartz M (2015) Breaking immune tolerance by targeting Foxp3(1) regulatory T cells mitigates Alzheimer’s disease pathology. Nat Commun 6:7967
Bloom GS (2014) Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 71:505–508
Bondi M et al (2017) Alzheimer’s disease: past, present, and future. J Int Neuropsychol Soc 23(9–10):818–831. https://doi.org/10.1017/S135561771700100X
Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259
Chitnis T, Weiner HL (2017) CNS inflammation and neurodegeneration. J Clin Invest 127(10):3577–3587. https://doi.org/10.1172/JCI90609
Dhillon J-KS, Riffe C, Moore BD (2017) A novel panel of α-synuclein antibodies reveal distinctive staining profiles in synucleinopathies. PLoS One 12(9):e0184731. https://doi.org/10.1371/journal.pone.0184731
Dobson CM (2003) Protein folding and misfolding. Nature 426:884–890
Faras H, Al Ateeqi N, Tidmarsh L (2010) Autism spectrum disorders. Ann Saudi Med 30(4):295–300. https://doi.org/10.4103/0256-4947.65261
Felli V, Di Sibio A, Anselmi M, Gennarelli A, Sucapane P (2014) Progressive multifocal leukoencephalopathy following treatment with rituximab in an HIV-negative patient with non-Hodgkin lymphoma. Neuroradiol J 27:657–664. https://doi.org/10.15274/NRJ-2014-10087
Ferreira SA, Romero-Ramos M (2018) Microglia response during Parkinson’s disease: alpha-synuclein intervention. Front Cell Neurosci 12:247. https://doi.org/10.3389/fncel.2018.00247
Fields CR, Bengoa-Vergniory N, Wade-Martins R (2019) Targeting alpha-Synuclein as a therapy for Parkinson’s disease. Front Mol Neurosci 12:299. https://doi.org/10.3389/fnmol.2019.00299
Games D, Valera E, Spencer B (2014) Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates Neurodegeneration and propagation in Parkinson’s disease-like models. J Neurosci 34(28):9441–9454
George S, Brundin P (2015) Immunotherapy in Parkinson’s disease: micromanaging alpha-Synuclein aggregation. J Parkinsons Dis 5:413–424. https://doi.org/10.3233/JPD-150630
Ghiglieri V, Calabrese V, Calabresi P (2018) Alpha-synuclein: from early synaptic dysfunction to neurodegeneration. Front Neurol 9:295. https://doi.org/10.3389/fneur.2018.00295
Giannakopoulos P et al (2003) Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease. Neurology 60:1495–1500
Goldenberg MM (2012) Multiple sclerosis review. Pharm Therapeut 37(3):175–184
Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM et al (2015) Neuroinflammation in Alzheimer’s disease. Lancet Neurol 14:388–405
Hock C, Konietzko U, Streffer JR et al (2003) Antibodies against b-amyloid slow cognitive decline in Alzheimer’s disease. Neuron 38:547–554
Hutchinson M (2007) Natalizumab: a new treatment for relapsing remitting multiple sclerosis. Ther Clin Risk Manag 3(2):259–268
Jacob S, Rajabally YA (2009) Current proposed mechanisms of action of intravenous Immunoglobulins in inflammatory neuropathies. Curr Neuropharmacol 7:337–342
Janus C, Pearson J, McLaurin J et al (2000) Ab peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. Nature 408:979–982
Jolles S, Sewell WAC, Misbah SA (2005) Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 142:1–11
Kunis G, Baruch K, Miller O, Schwartz M (2015) Immunization with a myelin-derived antigen activates the brain’s choroid plexus for recruitment of immunoregulatory cells to the CNS and attenuates disease progression in a mouse model of ALS. J Neurosci 35:6381–6393
Lavery AM, Verhey LH, Waldman AT (2014) Outcome measures in relapsing-remitting multiple sclerosis:capturing disability and disease progression in clinical trials. Mult Scler Int 2014:262350. https://doi.org/10.1155/2014/262350
Li Z, Richards S, Surks HK, Jacobs A, Panzara MA (2018) Clinical pharmacology of alemtuzumab, an anti-cd52 immunomodulator, in multiple sclerosis. Clin Exp Immunol 194(3):295–314
Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, David Peske J, Derecki NC, Castle D, Mandell JW, Lee KS, Harris TH, Kipnis J (2015) Structural and functional features of central nervous system lymphatic vessels. Nature 523(7560):337–341. https://doi.org/10.1038/nature14432
Mahmood R, Arif M, Muhammad SQ, Abdul M, Peter NP, Muhammad A (2014) Recent updates in the treatment of neurodegenerative disorders using natural compounds. Evid Based Complement Alternat Med 2014:979730. https://doi.org/10.1155/2014/979730
Mandler M, Valera E, Rockenstein E (2014) Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials. Acta Neuropathol 127(6):861–879. https://doi.org/10.1007/s00401-014-1256-4
Martin R (2012) Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing–remitting multiple sclerosis. Clin Immunol 142:9–14
Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL (2015) Alzheimer’s disease. Nat Rev Dis Primers 1:15056
Medawar PB (1948) Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 29:58–69
Menéndez-Gonzále M, Padilla-Zambrano HS (2018) Clearing extracellular alpha-Synuclein from cerebrospinal fluid: a new therapeutic strategy in Parkinson’s disease. Brain Sci 8:52. https://doi.org/10.3390/brainsci8040052
Meyer PF, Tremblay-Mercier J, Leoutsakos J, Madjar C, Lafaille-Maignan ME, Savard P, Rosa-Neto J, Poirier PE, Breitner J, Prevent-AD Research Group (2019) INTREPAD: a randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease. [Published erratum appears in 2019 Neurology 93: 371]. Neurology 92:e2070–e2080
Mhyre TR, Boyd JT, Hamill RW, Maguire-Zeiss KA (2012) Parkinson’s disease. Subcell Biochem 65:389–455. https://doi.org/10.1007/978-94-007-5416-4_16
Mroczko B, Groblewska M, Litman-Zawadzka A (2019) The role of protein misfolding and tau oligomers (TauOs) in Alzheimer’s disease (AD). Int J Mol Sci 20(19):4661. https://doi.org/10.3390/ijms20194661
Mullard A (2016) Pharma pumps up anti-tau Alzheimer pipeline despite first phase III failure. Nat Rev Drug Discov 15:591–592
Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller R (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-b peptide: a case report. Nat Med 9:448–452
Nopoulos PC (2016) Huntington disease: a single-gene degenerative disorder of the striatum. Dialogues Clin Neurosci 18(1):91–98
Panza F, Lozupone M, Dibello V, Greco A, Daniele A, Seripa D, Logroscino G, Imbimbo BP (2019) Are antibodies directed against amyloid-b (Ab) oligomers the last call for the Ab hypothesis of Alzheimer’s disease? Immunotherapy 11:3–6
Poggiolini I, Saverioni D, Parchi P (2013) Prion protein misfolding, strains, and neurotoxicity: an update from studies on mammalian prions. Int J Cell Biol 2013:910314. https://doi.org/10.1155/2013/910314
Popescu BFG, Pirko I, Lucchinetti CF (2013) Pathology of multiple sclerosis: where do we stand. Continuum (Minneap Minn) 19(4):901–921
Qi F, Zuo Z, Yang J, Hu S, Yang Y, Yuan Q, Zou J, Guo K, Yao Z (2017) Combined effect of BCG vaccination and enriched environment promote neurogenesis and spatial cognition via a shift in meningeal macrophage M2 polarization. J Neuroinflammation 14:32
Ravi R, Hemachandra PR (2016) Amyloid-beta and phosphorylated tau accumulations cause abnormalities at synapses of Alzheimer’s disease neurons. J Alzheimers Dis 57(4):1–25. https://doi.org/10.3233/JAD-160612
Rietdijk CD, Perez-Pardo P, Garssen J, van Wezel RJA (2017) Exploring Braak’s hypothesis of Parkinson’s disease. Front Neurol 8:1–9. https://doi.org/10.3389/fneur.2017.00037
Rosenzweig N, Dvir-Szternfeld R, Tsitsou-Kampeli A, Keren-Shaul H, Ben-Yehuda H, Weill-Raynal P, Cahalon L, Kertser A, Baruch K, Amit I et al (2019) PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model. Nat Commun 10:465
Sanchez-Guajardo V, Annibali A, Jensen PH (2013) Alpha-Synuclein vaccination prevents the accumulation of Parkinson disease Y like pathologic inclusions in striatum in association with regulatory T cell recruitment in a rat model. J Neuropathol Exp Neurol 72:7
Schenk D, Barbour R, Dunn W et al (1999) Immunization with amyloid-b attenuates Alzheimer-disease like pathology in the PDAPP mouse. Nature 400:173–177
Selkoe DJ (2004) Cell biology of protein misfolding: the examples of Alzheimer’s and Parkinson’s diseases. Nat Cell Biol 6:1054–1061
Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer’s disease. EMBO Mol Med 8:595–608
Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 1:a006189
Shahaduzzaman M, Nash K, Hudson C, Sharif M, Grimmig B, Lin X et al (2015) Anti-human α-Synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-Synuclein rat model of Parkinson’sDisease. PLoS One 10(2):e0116841. https://doi.org/10.1371/journal.pone.0116841
Song EJ, Jeon SG, Kim KA, Kim JI, Moon M (2017) Restricted CD41 T cell receptor repertoire impairs cognitive function via alteration of Th2cytokine levels. Neurogenesis (Austin) 4:e1256856
Sorensen PS, Blinkenberg M (2016) The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. Ther Adv Neurol Disord 9(1):44–52. https://doi.org/10.1177/1756285615601933
Statland JM, Barohn RJ, McVey AL, Katz JS, Dimachkie MM (2015) Patterns of weakness, classification of motor neuron disease, and clinical diagnosis of sporadic amyotrophic lateral sclerosis. Neurol Clin 33(4):735–748. https://doi.org/10.1016/j.ncl.2015.07.006
Stefanis L (2012) A-Synuclein in Parkinson’s disease. Cold Spring Harb Perspect Med 4:a009399
Stower H (2018) Searching for Alzheimer’s disease therapies. Nat Med 24:894–897
Taylor JP, Hardy J, Fischbeck KH (2002) Toxic proteins in neurodegenerative disease. Science 296:1991–1995
Vandenberghe R, Riviere ME, Caputo A, Sovago J, Maguire RP, Farlow M et al (2016) Active Aβ immunotherapy CAD106 in Alzheimer’s disease: a phase 2b study. Alzheimers Dement 3(1):10–22
Vick JS, Askwith CC (2015) ASICs and neuropeptides. Neuropharmacology 94:36–41. https://doi.org/10.1016/j.neuropharm.2014.12.012
Villeda SA, Plambeck KE, Middeldorp J, Castellano JM, Mosher KI, Luo J, Smith LK, Bieri G, Lin K, Berdnik D et al (2014) Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. Nat Med 20:659–663
Wang J, Gu BJ, Masters CL, Wang YJ (2017) A systemic view of Alzheimer disease—insights from amyloid-b metabolism beyond the brain. Nat Rev Neurol 13:612–623. [published erratum appears in 2017 Nat. Rev. Neurol. 13: 703]
Wilcock DM, Colton CA (2008) Anti-amyloid-beta immunotherapy in Alzheimer’s disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis 15(4):555–569. https://doi.org/10.3233/jad-2008-15404
Zella MAS, Metzdorf J (2019) Novel immunotherapeutic approaches to target alpha-Synuclein and related Neuroinflammation in Parkinson’s disease. Cell 8:105. https://doi.org/10.3390/cells8020105
Zhang G, Wang T, Xia Y (2018) New perspectives on roles of alpha-synuclein in Parkinson’s disease. Front Aging Neurosci 10:370. https://doi.org/10.3389/fnagi.2018.00370
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Kamthe, D., Gosavi, N., Nikam, V.S. (2021). Immunotherapy in Neurodegenerative Disorders. In: Sawarkar, S.P., Nikam, V.S., Syed, S. (eds) Immunotherapy – A Novel Facet of Modern Therapeutics. Springer, Singapore. https://doi.org/10.1007/978-981-15-9038-2_5
Download citation
DOI: https://doi.org/10.1007/978-981-15-9038-2_5
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-9037-5
Online ISBN: 978-981-15-9038-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)